Daniel Ziemek
Overview
Explore the profile of Daniel Ziemek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
2009
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krishna C, Chiou J, Sakaue S, Kang J, Christensen S, Lee I, et al.
Nat Commun
. 2024 Jul;
15(1):6469.
PMID: 39085222
Genetic variation in the human leukocyte antigen (HLA) loci is associated with risk of immune-mediated diseases, but the molecular effects of HLA polymorphism are unclear. Here we examined the effects...
2.
Hedman A, Winter E, Yoosuf N, Benita Y, Berg L, Brynedal B, et al.
Sci Rep
. 2023 Jun;
13(1):10058.
PMID: 37344505
Rheumatoid arthritis (RA) is an autoimmune disease characterized by systemic inflammation and is mediated by multiple immune cell types. In this work, we aimed to determine the relevance of changes...
3.
Brynedal B, Yoosuf N, Ulfarsdottir T, Ziemek D, Maciejewski M, Folkersen L, et al.
Front Med (Lausanne)
. 2023 Apr;
10:1146353.
PMID: 37051216
Background: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA), but failure of satisfying treatment response occurs in a significant proportion of patients. Here we present a longitudinal...
4.
Vetrano S, Bouma G, Benschop R, Birngruber T, Costanzo A, DHaens G, et al.
Front Immunol
. 2022 Nov;
13:1002629.
PMID: 36439150
Immune mediated inflammatory diseases (IMIDs) are a heterogeneous group of debilitating, multifactorial and unrelated conditions featured by a dysregulated immune response leading to destructive chronic inflammation. The immune dysregulation can...
5.
Harshfield E, Fauman E, Stacey D, Paul D, Ziemek D, Ong R, et al.
BMC Med
. 2021 Sep;
19(1):232.
PMID: 34503513
Background: Genetic, lifestyle, and environmental factors can lead to perturbations in circulating lipid levels and increase the risk of cardiovascular and metabolic diseases. However, how changes in individual lipid species...
6.
Hassan-Zahraee M, Ye Z, Xi L, Baniecki M, Li X, Hyde C, et al.
Inflamm Bowel Dis
. 2021 Aug;
28(3):434-446.
PMID: 34427649
Background: The first-in-class treatment PF-06480605 targets the tumor necrosis factor-like ligand 1A (TL1A) molecule in humans. Results from the phase 2a TUSCANY trial highlighted the safety and efficacy of PF-06480605...
7.
Yoosuf N, Maciejewski M, Ziemek D, Jelinsky S, Folkersen L, Muller M, et al.
Rheumatology (Oxford)
. 2021 Jun;
61(4):1680-1689.
PMID: 34175943
Objectives: Advances in immunotherapy by blocking TNF have remarkably improved treatment outcomes for Rheumatoid arthritis (RA) patients. Although treatment specifically targets TNF, the downstream mechanisms of immune suppression are not...
8.
Westerlind H, Maciejewski M, Frisell T, Jelinsky S, Ziemek D, Askling J
ACR Open Rheumatol
. 2021 Jun;
3(7):457-463.
PMID: 34085401
Objective: The objectives of this study were to assess the 1-year persistence to methotrexate (MTX) initiated as the first ever conventional synthetic disease-modifying antirheumatic drug in new-onset rheumatoid arthritis (RA)...
9.
Maciejewski M, Sands C, Nair N, Ling S, Verstappen S, Hyrich K, et al.
Sci Rep
. 2021 Apr;
11(1):7266.
PMID: 33790392
Methotrexate (MTX) is a common first-line treatment for new-onset rheumatoid arthritis (RA). However, MTX is ineffective for 30-40% of patients and there is no way to know which patients might...
10.
Smith A, Walsh J, Long J, Davis C, Henstock P, Hodge M, et al.
BMC Bioinformatics
. 2020 Mar;
21(1):119.
PMID: 32197580
Background: The ability to confidently predict health outcomes from gene expression would catalyze a revolution in molecular diagnostics. Yet, the goal of developing actionable, robust, and reproducible predictive signatures of...